The discovery of activating PIK3CA mutations in PROS has not only yielded a new target for much-needed precision therapies, but has also exposed gaps in our understanding of PI3K signaling in human cancer and embryonic development (see Outstanding Questions and Box 1). This evidence concerns the gene PIK3CA and cancer.